Analyst Ratings For Array Biopharma Inc (NASDAQ:ARRY)
Today, Cowen set its price target on Array Biopharma Inc (NASDAQ:ARRY) to $22.00 per share.
There are 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Array Biopharma Inc (NASDAQ:ARRY) is Buy with a consensus target price of $23.3750 per share, a potential 55.42% upside.
Some recent analyst ratings include
- 9/17/2018-Array Biopharma Inc (NASDAQ:ARRY) has coverage initiated with a Buy rating
- 6/24/2018-Array Biopharma Inc (NASDAQ:ARRY) had its Overweight ➝ Buy rating reiterated by Cantor Fitzgerald with a $26.00 price target
- On 9/19/2018 Lunsen Gil J Van, Director, sold 18,000 with an average share price of $14.76 per share and the total transaction amounting to $265,680.00.
- On 9/4/2018 Victor Sandor, Insider, sold 9,687 with an average share price of $15.38 per share and the total transaction amounting to $148,986.06.
- On 8/15/2018 Jason Haddock, CFO, sold 20,000 with an average share price of $13.92 per share and the total transaction amounting to $278,400.00.
- On 7/30/2018 Jason Haddock, CFO, sold 25,000 with an average share price of $14.87 per share and the total transaction amounting to $371,750.00.
- On 7/18/2018 Lunsen Gil J Van, Director, sold 21,500 with an average share price of $16.56 per share and the total transaction amounting to $356,040.00.
- On 7/6/2018 Kyle Lefkoff, Director, sold 50,000 with an average share price of $17.45 per share and the total transaction amounting to $872,500.00.
- On 6/27/2018 Andrew R Robbins, COO, sold 17,964 with an average share price of $17.74 per share and the total transaction amounting to $318,681.36.
Recent Trading Activity for Array Biopharma Inc (NASDAQ:ARRY)
Shares of Array Biopharma Inc closed the previous trading session at 15,04 +0,61 4,23 % with 15 shares trading hands.